Blood
Articles in this Issue
Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial
Abstract Background Patients with relapsed/refractory (RR) DLBCL ineligible for chimeric antigen receptor T-cell therapy and/or autologous s...
Thalidomide and hydroxyurea combination therapy in transfusion-dependent beta-thalassemia major: A real-world retrospective analysis
Abstract Thalidomide and Hydroxyurea Combination Therapy in Transfusion-Dependent Beta-Thalassemia Major: A Real-World Retrospective Analysi...
IL-17 as a targetable pathway to reverse early NK cell dysregulation in high-risk MDS with late relapse
Abstract Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by ineffective hematopoiesis, high risk o...
Remission instead of eradication? MEK inhibition in primary refractory childhood LCH
Abstract Background Langerhans Cell Histiocytosis (LCH) is a clonal myeloid neoplasm caused by activating somatic mutations in the MAPK sign...
The efficacy of Obinutuzumab , zanubrutinib combined with pomalidomide and Venetoclax for the treatment of high-risk mutated Mantle Cell Lymphoma (MCL): A prospective, open-label, single-arm study
Abstract High-risk MCL lacks effective treatment options and has a poor prognosis, posing challenges in management. The guidelines recommend...
Target enrichment long-range sequencing (TLES) reveals structural variations missed by PEM-seq
Abstract Introduction: Genome editing technologies, such as clustered regularly interspaced short palindromic repeats (C...
Pan-leukemia 3D genomic profile reveals extreme long polycomb loop in subset of CEBPA mutated AMLs sensitive to EZH2 inhibition
Abstract Chromosomal loops are CTCF–cohesin-mediated 3D genomic structures in the mammalian nucleus. In addition to these CTCF–cohesin loops...
Strengthening the referral pathway: Community oncology clinician perspectives on referring to academic cancer centers
Abstract Introduction: Cancer clinical trials (CCTs) are essential to advancing treatment options for patients with hema...
Anti-CD38 targeted radiation is effective and enhances CAR-T cell recruitment and expansion in resistant extramedullary multiple myeloma
Abstract Multiple myeloma (MM) cell proliferation is typically confined to the bone marrow (BM) niche (intramedullary disease, IMD). However...
Racial and socioeconomic disparities in transfusion utilization among hospitalized sickle cell disease patients: An analysis of the 2022 national inpatient sample
Abstract Background Sickle cell disease (SCD) often requires inpatient management for acute complications, including severe anemia, vaso-occ...
High versus low-cost intravenous iron in Medicare: Utilization patterns of iron infusions in traditional fee-for-service Medicare and Medicare advantage for iron deficiency anemia
Abstract Background Iron deficiency anemia (IDA) can be managed with intravenous (IV) iron when oral supplements are ins...
Metabolic pathway signatures unpinning response to CD19 CAR T-cell therapy in aggressive B-cell non-Hodgkin's lymphoma
Abstract Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable response rates in relapsed/refractory aggressive B-cell...
Temporal trends and disparities in cardiovascular Disease–Related mortality in older adults with co-morbid anemia from 1999 to 2023 in the United States: A CDC wonder database analysis
Abstract Introduction: Anemia and cardiovascular disease (CVD) are common and interrelated diseases that significantly contribute to morbidi...
Health-related quality of life (HRQoL) in real-world patients with cutaneous T cell lymphoma (CTCL): Evaluation of patient reported outcomes using the Skindex-16 in a multidisciplinary CTCL clinic
Abstract Background Cutaneous T-cell lymphomas (CTCLs) are a rare group of heterogenous lymphomas that affect the skin...
Development of HPB-092: A novel dual kinase inhibitor targeting FLT3 and IRAK4 for the treatment of relapsed/refractory Acute Myeloid Leukemia (RR-AML)
Abstract Fms-like tyrosine kinase 3 (FLT3) is a clinically validated oncogene in acute myeloid leukemia (AML), while interleukin-1 receptor-...
Pre-transplant αTREC diversity reflects thymic function and independently predicts mortality following allogeneic hematopoietic cell transplantation
Abstract Introduction: Reliable biomarkers to predict mortality after allogeneic hematopoietic cell transplantation (allo-HCT) are lacking....
Transformed FL shows improved survival after CAR T-cell therapy compared to de novo LBCL, but early transformation (<12 months) defines a poor-risk subgroup: Results from a nationwide cohort
Abstract Background Large B-cell lymphoma (LBCL) can arise from transformation of indolent lymphomas, most commonly follicular lymphoma (FL)...
Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age ≥60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study
Abstract Background We performed a prospective study evaluating a baseline GA battery and clinical outcomes in fit older...
Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort
Abstract Introduction: T-PLL is a rare, aggressive leukemia with poor prognosis and limited therapies. Previous studies on T-PLL patients re...
TGF-β regulates CD123 and chemotherapy resistance in Acute Myeloid Leukemia stem cells
Abstract Acute myeloid leukemia (AML) exhibits a hierarchical cellular organisation, with a minor fraction of self-renewing leukemic stem ce...
In silico design of degron tags for precise modulation of CAR T-cell activity using clinically utilized drugs
Abstract Introduction Over the past decade, Chimeric Antigen Receptor (CAR) T-cell therapies have transformed the treatm...
Asciminib for newly diagnosed chronic myeloid leukemia: Results from A phase II trial
Abstract Background Asciminib is a Specifically Targeting the ABL1 Myristoyl Pocket (STAMP) inhibitor that demonstrated its safety and effic...
Oral decitabine/cedazuridine in combination with venetoclax in treatment-naïve high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia: Updates of a Phase 1/2 clinical trial
Abstract Background: The standard of care treatment for patients with high-risk myelodisplastic syndromes (HR-MDS) and chronic myelomonocyti...
Incidence of second primary malignancies in patients with hematologic malignancies treated with next-generation bruton tyrosine kinase (BTK) inhibitors: A meta-analysis of randomized controlled trials
Abstract Background: Second primary malignancies (SPMs) have emerged as a clinically relevant concern in patients with h...
Comparison of different dose of anti-T lymphocyte globulin (ATLG) in haploidentical HSCT for gvhd prophylaxis
Abstract Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curative option for various hematologic maligna...